Tocilizumab

MedicationExperimental0 reviews

—

Average score out of 5

Experimental — This treatment is under research. Available data is limited. Consult your doctor before making any decision.

Tocilizumab is a monoclonal antibody that blocks the interleukin-6 (IL-6) receptor, reducing systemic inflammation. It is being investigated in Long COVID for its potential to target the persistent inflammation that may underlie some symptoms.

Brand names

RoActemra

Information

Subcategory: interleukin-6 receptor antagonist
Evidence level: 2/5
Evidence type: mechanistic rationale and case series

Share your experience

Your feedback helps thousands of people find what really works.

Join the community